Fusion Medical Technologies
This article was originally published in The Gray Sheet
Executive SummarySecond-generation FloSeal matrix hemostatic sealant gains FDA market go-ahead. Combining specially engineered collagen-derived particles and topical thrombin, the product's advantages over the original topical sealant include easier preparation and deliverability, Fusion claims, as well as the ability to stop heavier bleeding in surgical procedures
You may also be interested in...
At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.
Health technology assessment body NICE is consulting on draft guidance that recommends Axonics' device for overactive bladder.